246 related articles for article (PubMed ID: 7659484)
21. Acellular pertussis vaccines: neutralization by immune sera of the lethality of pertussis toxin and viable Bordetella pertussis for chick embryos.
Calver GA
Biologicals; 1999 Jun; 27(2):143-7. PubMed ID: 10600203
[TBL] [Abstract][Full Text] [Related]
22. Differences of humoral and cellular immune response to an acellular pertussis booster in adolescents with a whole cell or acellular primary vaccination.
Rieber N; Graf A; Belohradsky BH; Hartl D; Urschel S; Riffelmann M; Wirsing von König CH; Liese J
Vaccine; 2008 Dec; 26(52):6929-35. PubMed ID: 18852002
[TBL] [Abstract][Full Text] [Related]
23. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
[TBL] [Abstract][Full Text] [Related]
24. Serologic response and antibody-titer decay in adults with pertussis.
Heininger U; Cherry JD; Stehr K
Clin Infect Dis; 2004 Feb; 38(4):591-4. PubMed ID: 14765356
[TBL] [Abstract][Full Text] [Related]
25. Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection.
Hallander HO; Ljungman M; Jahnmatz M; Storsaeter J; Nilsson L; Gustafsson L
APMIS; 2009 Sep; 117(9):660-71. PubMed ID: 19703126
[TBL] [Abstract][Full Text] [Related]
26. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
[TBL] [Abstract][Full Text] [Related]
27. Antibody responses after vaccination and disease against leukocytosis promoting factor, filamentous hemagglutinin, lipopolysaccharide and a protein binding to complement-fixing antibodies induced during whooping cough.
Winsnes R; Lønnes T; Møgster B; Berdal BP
Dev Biol Stand; 1985; 61():353-65. PubMed ID: 2872124
[TBL] [Abstract][Full Text] [Related]
28. Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine.
Thomas MG; Ashworth LA; Miller E; Lambert HP
J Infect Dis; 1989 Nov; 160(5):838-45. PubMed ID: 2572651
[TBL] [Abstract][Full Text] [Related]
29. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the protective effects of the pertussis acellular vaccine with the component vaccine, which have different amounts of fimbriae, against the experimental aerosol infection of mice with Bordetella pertussis.
Morokuma K; Ginnaga A; Nishihara T; Tsunoda S; Furukawa M; Aihara K; Sakoh M
Dev Biol Stand; 1991; 73():223-32. PubMed ID: 1685713
[TBL] [Abstract][Full Text] [Related]
31. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.
Storsaeter J; Hallander HO; Gustafsson L; Olin P
Vaccine; 1998 Dec; 16(20):1907-16. PubMed ID: 9796042
[TBL] [Abstract][Full Text] [Related]
32. [Acellular pertussis vaccine].
Wiedermann G; Ambrosch F; Vanura H
Wien Med Wochenschr; 1991; 141(12):270-2. PubMed ID: 1949820
[TBL] [Abstract][Full Text] [Related]
33. [Humoral response to the injection of acellular Pertussis vaccine].
Zakharova NS; Remova TN; Britsina MV; Shmeleva EI; Mertsalova NU; Zaĭtsev EM; Ozeretskovskaia MN; Bazhanova IG; Ermolova EV
Zh Mikrobiol Epidemiol Immunobiol; 2001; (6):40-4. PubMed ID: 11881494
[TBL] [Abstract][Full Text] [Related]
34. Bordetella pertussis fimbriae (Fim): relevance for vaccines.
Gorringe AR; Vaughan TE
Expert Rev Vaccines; 2014 Oct; 13(10):1205-14. PubMed ID: 25102891
[TBL] [Abstract][Full Text] [Related]
35. A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines.
Barkoff AM; Guiso N; Guillot S; Xing D; Markey K; Berbers G; Mertsola J; He Q
J Immunol Methods; 2014 Jun; 408():142-8. PubMed ID: 24925807
[TBL] [Abstract][Full Text] [Related]
36. How to make sense of pertussis immunogenicity data.
Olin P; Hallander HO; Gustafsson L; Reizenstein E; Storsaeter J
Clin Infect Dis; 2001 Dec; 33 Suppl 4():S288-91. PubMed ID: 11709761
[TBL] [Abstract][Full Text] [Related]
37. Does whole-cell pertussis vaccine protect black South African infants? Assessment of post-vaccination events and antibody responses to pertussis toxin, filamentous haemagglutinin and agglutinogens 2 and 3.
Ramkissoon A; Coovadia HM; Loening WE; Ndlovana M
S Afr Med J; 1991 Jun; 79(11):645-9. PubMed ID: 1675492
[TBL] [Abstract][Full Text] [Related]
38. Antibody Specificity Following a Recent
Raeven RHM; van der Maas L; Pennings JLA; Fuursted K; Jørgensen CS; van Riet E; Metz B; Kersten GFA; Dalby T
Front Immunol; 2019; 10():1364. PubMed ID: 31275314
[No Abstract] [Full Text] [Related]
39. Seroprevalence of Bordetella pertussis antibodies in mothers and their newborn infants.
Gonik B; Puder KS; Gonik N; Kruger M
Infect Dis Obstet Gynecol; 2005 Jun; 13(2):59-61. PubMed ID: 16011994
[TBL] [Abstract][Full Text] [Related]
40. Acellular pertussis vaccines and the role of pertactin and fimbriae.
Poolman JT; Hallander HO
Expert Rev Vaccines; 2007 Feb; 6(1):47-56. PubMed ID: 17280478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
